Gaxilose - Venter Pharma
Alternative Names: 4-galactosyl-xylose; 4-O-β-D galactopyranosyl-D-xylose; LacTESTLatest Information Update: 09 Jan 2026
At a glance
- Originator Venter Pharma
- Class Diagnostic agents; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Digestive system disorders
Most Recent Events
- 29 Sep 2025 Preclinical trials in Digestive system disorders (Diagnosis, In children) in Spain (PO), prior to January 2025 (CTIS2023-504232-18-00)
- 08 Sep 2025 Venter Pharma plans to initiate a phase I trial for Digestive system disorder (Diagnosis, In children) in (Spain) (CTIS2023-504232-18-00)
- 01 Sep 2025 Venter Pharma plans to initiate a phase I trial for Lactose-intolerance (Diagnosis) in Spain (PO) in September 2025 (CTIS2025-521308-23-00)